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Abstract
The intersection of immunotherapy and radiation oncology is a rapidly evolving area of pre-
clinical and clinical investigation. The strategy of combining radiation and immunotherapy to
enhance local and systemic antitumor immune responses is intriguing yet largely unproven in the
clinical setting because the mechanisms of synergy and the determinants of therapeutic response
remain undeﬁned. In recent years, several noninvasive molecular imaging approaches have
emerged as a platform to interrogate the tumor immune microenvironment. These tools have the
potential to serve as robust biomarkers for cancer immunotherapy and may hold several advantages
over conventional anatomic imaging modalities and contemporary invasive tissue acquisition
techniques. Given the key and expanding role of precision imaging in radiation oncology for
patient selection, target delineation, image guided treatment delivery, and response assessment,
noninvasive molecular-speciﬁc imaging may be uniquely suited to evaluate radiation/
immunotherapy combinations. Herein, we describe several experimental imaging-based
strategies that are currently being explored to characterize in vivo immune responses, and we
review a growing body of preclinical data and nascent clinical experience with immuno-positron
emission tomography molecular imaging as a putative biomarker for cancer immunotherapy.
Finally, we discuss practical considerations for clinical translation to implement noninvasive
molecular imaging of immune checkpoint molecules, immune cells, or associated elements of the
antitumor immune response with a speciﬁc emphasis on its potential application at the interface of
radiation oncology and immuno-oncology.
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Introduction
The general premise of cancer immunotherapy is to
induce, augment, or reinvigorate the host’s antitumor
immune response. The disruption of immune-inhibitory
ligand-receptor interactions with immune checkpoint
blockade (ICB) has been a transformative advancement in
cancer immunotherapy.1 In particular, the blockade of the
programmed cell death protein 1 (PD-1)/programmed
death-ligand 1 (PD-L1) axis, which is an important
mechanism of immune evasion within the tumor micro-
environment (TME), has resulted in impressive clinical
responses across a spectrum of malignancies. Despite this
undeniable progress, the reality remains that only subsets
of patients beneﬁt from anti-PD-1/anti-PD-L1 ICB.
To address this issue, there is a pressing need to
identify biomarkers that may guide patient selection and
assist the evaluation of treatment response.2 This has
proven to be a challenging task given the complexity and
dynamic nature of antitumor immune responses. Mono-
therapy with ICB is increasingly unlikely to be sufﬁcient
treatment for most patients, and combination approaches
that involve immunotherapy with standard-of-care thera-
pies (eg, radiation therapy, surgery, chemotherapy, and
targeted therapy) or other immuno-oncology agents (eg,
dual ICB, cancer vaccines, adoptive cellular therapy,
T-cell agonists, and immunocytokines) are a future di-
rection to improve clinical outcomes.3 Radiation therapy
has emerged as an appealing partner for cancer immu-
notherapy given its dual cytotoxic and immunomodula-
tory properties. However, much work is needed to
optimize potential synergies, and additional validation of
this approach in humans is desperately needed.4e6
Noninvasive molecular imaging has become an inte-
gral component of cancer diagnosis and management.
Molecular imaging can provide additional tumor- and
immune-speciﬁc information beyond conventional x-ray
computed tomography (CT) or magnetic resonance
anatomic imaging. Because of the capacity of molecular
imaging to noninvasively assay in vivo biological pro-
cesses with high resolution at a whole-body level, there is
considerable interest to develop this technology to guide
treatment in multiple oncologic indications.7 Immune
positron emission tomography (immuno-PET) describes a
facet of molecular imaging in which radio-labeled
monoclonal antibodies, engineered antibody fragments,
or peptides permit the direct imaging of molecularly
speciﬁc targets. An advantage of PET is its ability to
quantitatively measure and monitor molecular expression.
Together, these features hold tremendous promise as a
platform for biomarker-driven ICB and other cancer
immunotherapies.
Given the inextricable link between imaging and ra-
diation oncology, there is a unique opportunity to explore
immuno-PET and other molecular imaging tools to
evaluate radiation/immunotherapy combinations. These
emerging methods in PET may improve patient selection
and target delineation and ultimately may become a useful
tool for adaptive radiation planning as we collectively
strive toward personalized medicine in radiation
oncology.8,9
Biomarkers and cancer immunotherapy
At present, there is a paucity of validated biomarkers
for cancer immunotherapy. Several candidates, including
intratumoral cluster of differentiation (CD) 8þ T-cell
density/inﬁltration,10 tumor mutational burden,11,12
T-cell-inﬂamed/interferon (IFN)-ɣ-related gene signa-
ture,13 and intratumoral PD-L1 expression may help
predict response to ICB, although each metric is imper-
fect. Ultimately, a single measure may fail to capture the
tumor immune landscape.
Among these putative markers, assaying PD-L1 pro-
tein expression within the TME by immunohistochem-
istry (IHC) has received the most attention.14
Unfortunately, baseline PD-L1 expression has not
consistently predicted clinical response to PD-1/PD-L1
blockade in prospective studies of several cancer types.
Increased PD-L1 expression levels have generally corre-
lated positively with improved clinical outcomes, but
other studies have failed to support this association.15,16
As clinical responses are observed among PD-L1-
negative patients and within PD-L1 unselected cohorts,
the use of PD-L1 IHC as a patient selection criterion
could exclude patients who may beneﬁt from ICB and
highlights the need for better tools to characterize the
immune TME.
There are both technical and biological considerations
for these discrepancies in clinical reports. From a tech-
nical standpoint, differences in tissue preparation, assays
and detection antibodies, variable grading schemas, and
arbitrary cutoffs to deﬁne PD-L1 positivity, each limit
comparison and interpretation across studies and between
different anti-PD-1/PD-L1 pharmaceuticals.17 One rele-
vant issue that remains unresolved is the relative impor-
tance of PD-L1 expression on tumor cells, tumor-
inﬁltrating immune cells, or both.
Tumor cell expression is used by several assays to
determine PD-L1 status; however, studies in refractory
urothelial carcinoma have associated increased levels of
PD-L1 expression on immune cells with an increased
response to atezolizumab (anti-PD-L1).18 This conun-
drum of expression by cell type will likely extend to ra-
diation/immunotherapy combinations because radiation
modulates PD-L1 expression within the TME.19 Indeed,
various preclinical models have attributed synergy with
anti-PD-L1 therapies with either reversal of resistance that
is mediated by PD-L1-expressing tumor cells,20,21 or the
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depletion of tumor-inﬁltrating PD-L1-positive immune
cells22,23 (myeloid-derived suppressor cells).
Along these lines, immune checkpoint expression is
highly dynamic and context-dependent. This presents an
obstacle for tissue-based approaches, which can only
provide a static snapshot of the immune TME at the time
of biopsy or surgery and cannot monitor response to
therapy over time without additional invasive procedures.
PD-L1 expression can arise in response to an active
antitumor response as an adaptive immune resistance
mechanism24 and is also modulated/induced by various
therapies (including radiation therapy); therefore, to sur-
mise that PD-L1 expression at the time of tissue acqui-
sition also reﬂects the current state of the TME and can be
extrapolated to predict response may be an
oversimpliﬁcation.
Furthermore, signiﬁcant spatiotemporal variation and
discordance of immune checkpoint expression may exist
between the primary tumor and metastatic foci or between
metastatic lesions at multiple body sites/organs. To date,
studies have demonstrated that clinically meaningful
heterogeneity in PD-L1 expression can exist even within
the same tumor.25 This has clear implications for targeted
biopsies because sampling error (or undersampling) as
well as inter- and intratumor heterogeneity may yield
dramatically different results and could inﬂuence treat-
ment decisions if patients are selected based on PD-L1
IHC.
An ideal biomarker for cancer immunotherapy should
be able to assess dynamic changes over time and provide
whole-body real-time information. Noninvasive imaging
could address many of the aforementioned limitations
with contemporary approaches, and either circumvents
the need for invasive tissue acquisition or augments the
clinical value of invasive tissue acquisition. Further, serial
imaging to assess modulation of a target of interest within
the TME at baseline and in response to therapeutic
intervention may provide insight into potential mecha-
nisms of synergy. Although much of this discussion has
been dedicated to PD-L1 IHC-based assays, many of
these principles and considerations apply to other putative
immunotherapy biomarkers that rely on tissue-based
techniques and provide a rationale to explore immuno-
PET in cancer immunotherapy.
Radiologic evaluation and imaging-based
response criteria with immunotherapy
Conventional anatomic imaging is a reliable and
convenient approach to evaluate treatment response.
However, the traditional assessment criteria were
designed for and validated in patients treated with cyto-
toxic systemic therapies. Given the unique mechanisms of
action and distinct patterns of response that are associated
with immunotherapeutic intervention, a need to reﬁne
existing methodologies and develop new metrics that
more accurately capture clinically relevant responses is
widely recognized.26
The Response Evaluation Criteria in Solid Tumors
(RECIST) that were initially developed in 2000 and
revised in 2009 (RECIST v1.1) remain the gold standard
for response evaluation in clinical trials. Since then, our
experience with ICB has matured, and RECIST is
appreciated to possibly underestimate the clinical beneﬁt
that is associated with immunotherapy. This can lead to a
misinterpretation of treatment-related radiological
changes as progressive disease, which in turn leads to the
premature discontinuation of effective therapy. Certain
patterns, such as transient enlargement followed by sta-
bilization/shrinkage (pseudoprogression) or the appear-
ance of new lesions before subsequent response, are
representative of delayed response kinetics that can be
characteristic of immune-modulating agents. These pat-
terns of response are at risk for misclassiﬁcation by
RECIST.26
The clinical beneﬁt of treatment beyond RECIST-
deﬁned progression has been reported in patients with
metastatic renal cell carcinoma27,28 and melanoma29 who
are treated with anti-PD-1 ICB. Of note, pseudoprog-
ression remains a relatively rare phenomenon, and an
enlarging target lesion is much more likely to represent
true clinical progression. Pseudoprogression is hypothe-
sized to represent paradoxical tumor enlargement as a
consequence of immune-inﬁltration; thus, noninvasive
molecular imaging that can monitor T-cell trafﬁcking
might help distinguish this entity from clinical
progression.
The immune-related response criteria (irRC)30 were an
important ﬁrst step in the standardization of treatment
response evaluation for patients treated with immuno-
therapy in an effort to facilitate therapeutic decision
making. These criteria incorporate alternative methods to
calculate tumor burden and, importantly, reclassify
development of new or enlarging lesions so that they do
not automatically constitute progressive disease. An
eloquent comparison of the irRC and RECIST v1.1 in a
cohort of patients with melanoma who were treated with
pembrolizumab demonstrated that the conventional
RECIST underestimate the beneﬁt of immunotherapy in
approximately 15% of patients. A subset of patients with
discordant radiologic outcome (RECIST-deﬁned pro-
gression without irRC-deﬁned progressive disease)
experienced improved overall survival rates compared
with their counterparts with progressive disease with both
metrics.31
The development of criteria for immunotherapy-
treatment evaluation has been an iterative process
because the immune-response RECIST, immune
RECIST, and most recently the immune-modiﬁed
RECIST have each attempted to further reﬁne the
guidelines to assess the clinical beneﬁt of
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immunotherapy.32e35 Continued experience will likely
further reﬁne image-based approaches to monitor ICB
therapeutic outcomes.
Recent research has been focused on extracting addi-
tional radiologic information beyond uni- and bidimen-
sional measurements to better describe the host-tumor
immune contexture and infer clinical outcomes. An
intriguing report by Tang et al. has provided early evi-
dence that pretreatment quantitative imaging metrics may
be used as a surrogate for immune pathology-based ap-
proaches.36 Using lung cancer surgical pathology speci-
mens, patients were stratiﬁed by tumor PD-L1 expression
and CD3þ T-cell density into 4 subgroups, and pre-
treatment CT radiologic features were associated with
these immune TME parameters to develop an immune-
pathology informed radiomics model.
This novel radiomics model was successfully able to
discern subsets of patients with distinct survival outcomes
and immune-pathology features, which alludes to the po-
tential for this technology to be used as a prognostic or
predictive tool for patients treated with immunotherapy.
Similar efforts using magnetic resonance imaging (MRI)
have been pursued to identify speciﬁc immune populations
within the TME and might have future applications for
patient stratiﬁcation and selection for immunotherapy.37 A
small prospective study of ferumoxytol-enhanced MRI in
patients with lymphoma or bone sarcoma demonstrated
that tumor enhancement on T2-weighted sequences was
signiﬁcantly associated with the density of CD68þ/163þ
tumor-associated macrophages within the TME, which is
an immune subset that is generally correlated with adverse
outcomes and immunosuppression.38
Figure 1 Imaging changes in response to immunotherapy. (A-C) Axial contrast-enhanced computed tomography (CT) scan
demonstrating pseudoprogression in a patient treated with immunotherapy for advanced lung cancer. Marked interval enlargement of
right paratracheal lymph node (arrow) and development of new prevascular mediastinal adenopathy (arrow head) 6 weeks after
treatment compared with baseline (A-B). Follow-up CT scan 6 weeks later (12 weeks; C) demonstrates interval decrease in right
paratracheal node and disappearance of other nodes. (D-G) CT and fused [18F]FDG positron emission tomography/CT scan of met-
astatic melanoma patient on-treatment with immunotherapy with development of new FDG-avid mediastinal/hilar adenopathy (arrows,
D-E). Discontinuation of therapy because of suspected immune-related adverse event. Repeat imaging 6 weeks after treatment
termination (F-G) demonstrated substantial decrease in size and avidity of nodes. Biopsy test results demonstrated sarcoid-like reaction
and no evidence of malignancy. (H-I) Pre- and posttreatment nonenhanced axial CT images in patient with metastatic renal cell car-
cinoma treated with stereotactic body radiation therapy to posterior left lung lesion, followed by high-dose interleukin-2 with devel-
opment of ﬁbrotic changes (red) in site of stereotactic body radiation therapy and resolution of nonirradiated nodule (blue) in
contralateral lung. Treatment-related radiographic changes complicate assessment of local control.26,96 Images adapted with permission
for reuse 2018 American Cancer Society and 2012 American Association for the Advancement of Science.
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Functional imaging using positron emission tomogra-
phy with 2-deoxy-2-[ﬂuorine-18]-2-ﬂuoro-2-deoxy-D-
glucose integrated with computed tomography, or [18F]
FDG-PET/CT, which measures glucose metabolism as a
surrogate for tumor activity, has modernized staging,
treatment decision making, and response evaluation in
lymphoma and other malignancies.39,40 This technique
has also demonstrated promise as a tool to predict
response to immune-based treatments. Interestingly, in a
cohort of 20 patients with melanoma who were treated
with ICB, Cho et al. reported that an increase in [18F]FDG
uptake 3 to 4 weeks after initiation of therapy was asso-
ciated with favorable clinical outcomes at 4 months,
which prompted the authors to propose PET-based criteria
for the early prediction of eventual response (PET/CT
criteria for Early Prediction of Response to Immune
Checkpoint Inhibitor Therapy).39e41
Ultimately, [18F]FDG-PET/CT is not an optimal mo-
lecular imaging tool for immunotherapy because of its
lack of speciﬁcity at multiple levels. Increased glucose
utilization may be a function of tumor, stromal, or im-
mune cell processes and uptake often cannot be differ-
entiated from nonspeciﬁc inﬂammation or other
nonmalignant inﬂammatory conditions (see Fig 1).
However, other groups have argued a potential role for
earlier detection of immune-related adverse events that
could prevent avoidable treatment-related toxicity.26,42,43
Accordingly, novel molecular imaging strategies that are
more readily able to directly and indirectly assay the
tumor-immune interaction are being developed.44
Noninvasive molecular imaging of
immunotherapy
Immuno-PET uses radio-labeled antibodies or other
targeting scaffolds such as engineered proteins and pep-
tides that bind cell-surface molecular targets with mo-
lecular speciﬁcity. This provides high-resolution,
quantitative, in vivo molecular imaging information to
annotate target expression patterns and whole-body bio-
distribution. In the context of cancer immunotherapy,
preclinical models of immuno-PET have predominantly
focused on the expression of immunologically relevant
targets within the TME (ie, immune checkpoints and
effector molecules) or the detection and tracking of im-
mune cell populations (ie, T-cells subsets and chimeric
antigen receptor T-cells).
Imaging of PD-L1 has understandably attracted the
most attention given the clinical emergence of several
therapeutic antibodies that target the PD-1/PD-L1 axis and
the evolving importance of PD-L1 expression as a putative
biomarker of response to ICB. Encouragingly, preclinical
models have generally shown good concordance between
IHC- and imaging-based PD-L1 expression. Indeed, the
ability to noninvasively detect PD-L1 could transform
patient selection and treatment monitoring for ICB.
Further, an assessment of dynamic changes in expression
with serial imaging and the added spatiotemporal infor-
mation can help clinicians make real-time decisions to
guide therapy and provide a novel opportunity to more
comprehensively evaluate PD-L1 as a biomarker.45
An appreciation for the radioisotope, scaffold type, and
chelator and their ability to each alter the radiopharma-
ceutical properties, and thus the imaging result, is critical.
Ultimately, the impact of targeting vector molecular
weight, clearance characteristics, and binding afﬁnity on
in vivo pharmacokinetics and the complex’s radiochem-
istry must be optimized with consideration for the scien-
tiﬁc question at hand and the underlying
immunobiology.46 Radioisotope half-life dictates the
temporal window for imaging whereas radiometals
display different organ-speciﬁc tropism and patterns of
normal tissue biodistribution. To date, Zirconium-89
(89Zr; t1/2 Z 78.4 hr) and Copper-64 (
64Cu; t1/2 Z 12.7
hr) have been the most extensively studied radiometals
used for full-IgG antibody-based imaging because the
longer half-lives approach the biological half-life of these
proteins in circulation. Likewise, Fluorine-18 (t1/2Z 110
min) has been the radiolabel of choice for lower molec-
ular weight (and therefore faster clearing) tracers. We
summarize ongoing clinical molecular imaging/immuno-
PET efforts in Table 1.46
Radiometal labeling of antibodies uses established
chemical approaches to append isotope binding ligands
(chelates) to the protein. These methods enable only
minimal modiﬁcation of the antibody, including approved
ICB pharmaceutical formulations to be converted into
immuno-PET tools for in vivo testing. These efforts have
also extended to other immune checkpoints as 64Cu or
89Zr antihuman PD-1 (pembrolizumab, nivolumab)
immuno-PET radiotracers have detected PD-1 expression
on tumor-inﬁltrating lymphocytes (TIL) in humanized
mouse models47e49 and nonhuman primate studies.50
PD-L1 expression has also been successfully assayed
with 89Zr-C4 (IgG1 targeting the extracellular epitope of
human/mouse PD-L1) immuno-PET imaging in patient-
derived xenograft models.51 The ﬁrst in-human PD-L1
immuno-PET experience was reported at American Asso-
ciation for Cancer Research 2017 Annual Meeting.52
Sixteen patients underwent pretreatment 89Zr-atezo-
liuzmab immuno-PET imaging to evaluate normal organ
radiotracer uptake and correlate with baseline PD-L1
expression by IHC. The preliminary results demonstrated
heterogeneous tumor uptake even among tumors with
minimal PD-L1 expression by IHC as well as high back-
ground uptake in lymphoid tissues. Although these nascent
clinical ﬁndings demonstrate clinical feasibility, they also
indicate that substantial improvements are needed before
PD-L1 immuno-PET is ready for routine clinical use.
Radiolabeled antibodies have been the most common
scaffolds for PD-L1 immuno-PET studies,53e55 but there
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 Metastatic melanoma with 1 brain lesion
 Phase 1/2 feasibility study to determine optimal
dose/timing of [18F]PD-L1 immuno-PET and
biopsy of accessible lesion to correlate PD-L1
expression by IHC after each scan.






PD-L1 imaging in non-
small cell lung cancer
(PINNACLE)
 Metastatic NSCLC
 Phase 1/2 study of [89Zr]avelumab (anti-PD-L1)
immuno-PET to assess tumor and systemic
uptake of [89Zr]avelumab and potential to
predict avelumab treatment response














 Metastatic NSCLC, bladder cancer or TNBC
 Phase 1 to describe pharmacokinetics by
measuring SUV on [89Zr]MPDL3280A-PET
scans
 Tumor and immune cell PD-L1 expression
correlated to [89Zr]MPDL3280A tumor uptake






Functional imaging of T-






 Urothelial carcinoma eligible for NCT02451423
or planned anti-PD-1/PD-L1 per SOC
 Phase 2 to assess changes in [18F]AraG uptake
in primary and metastatic tumors in patients
treated with neoadjuvant atezolizumab or SOC
anti-PD-1/PD-L1.
 Secondary objective to correlate [18F]AraG
uptake with pathologic response in primary
tumor.










 Metastatic NSCLC refractory to platinum
 Phase 2 study of 2 immuno-PET scan with
nontherapeutic tracer dose (2 mg) of [89Zr]
pembrolizumabescan  cold therapeutic dose
of pembrolizumab
 Timing 1, 72, and 120 hours after tracer
injection.
 Safety assessment, describe SUV on [89Zr]
pembrolizuamb scan, characterize intra- and
interpatient heterogeneity in uptake, grade
uptake as positive/negative.












 Locally advanced/ metastatic NSCLC or
melanoma
 Description of whole body [89Zr]
pembrolizumab by measuring SUV on
immuno-PET scan to determine optimal tracer
dose and interval between tracer injection and
scanning.






Feasibility study of MRI





 Early phase 1 using whole-body diffusion-
weighted MRI and [18FF]FLT PET to evaluate
disease burden in patients treated with
pembrolizumab
 FLT-PET may be used as an early progressive
disease biomarker given close association
between FLT uptake and proliferative index
 Recruiting (n Z 20)
 Estimated completion
11/2024
(continued on next page)
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melanoma and use of
[11C] AMT PET as
baseline imaging
biomarker
 PD-1 inhibitor naïve unresectable/metastatic
melanoma
 Phase 2 study to associate 11-C-AMT PET at
baseline (SUVmax) with objective response rate
at 12 weeks to pembrolizumab
 AMT Z 1-methyl-D-tryptophaneexploratory
endpoint to correlate [11C]AMT PET with IDO
pathway by IHC (IDO, tryptophan, CD4/CD8
T-cells, Treg, MDSC, PD-L1, LAG-3/TIM-3/
GITR)











 Locally advanced/metastatic NSCLC, TNBC, or
urinary tract cancers
 Phase 2 trial of therapeutic MPDL3280A
(atezolizumab) with incorporation of 3
investigational imaging trials to assess baseline
activation status of immune system e [89Zr]
MPDL3280A PET, [89Zr]CD8 PET or [18F]FB-
IL2 PET












 [18F]FB-IL2 PET scan at baseline and week 6
after treatment with ipilimumab, nivolumab,
pembrolizumab or ipilimumab/nivolumab
 Comparison of baseline and 6-week [18F]FB-
IL2 immuno-PET to evaluate if treatment-
induced immune response is detected and
correlates with clinical outcome.
 [18F]FB-IL2 tumor uptake correlation with
IL2R-positive immune cells by IHC













 Phase 2 trial of 89Zr-labeled ipilimumab infused
within 2 hours of 1st and 2nd therapeutic
ipilimumab doses
 Visually and quantitative asses [89Zr]-
ipilimumab immuno-PET uptake in tumor
lesions and biodistribution at 2 timepoints
(baseline, 3-weeks). Secondary objective to
correlate tumor uptake with response, organ
uptake with toxicity.











 Selected solid tumors (NSCLC, small cell lung
cancer, head and neck squamous cell cancer,
TNBC, Merkel cell carcinoma, renal cell,
bladder, hepatocellular, gastroesophageal
cancer) and Hodgkin lymphoma
 Phase 1 dose-escalation study to evaluate safety,
tolerability, optimal time window/dose for
imaging and dosimetry
 Ability of [89Zr]-Dfd-IAB22M2C to detect
CD8þ T-cells e inert antibody fragment
against human CD8-antigen (mini-body)












 Recurrent high-grade glioma
 Phase 1 to assess safety of GRm13Z40-2 CTL
locoregional cellular immunotherapy
 Allogeneic CD8þ T-cell line genetically
modiﬁed to express IL-13-Zetakine and HyTK
in combination with IL-2.
 Completed (n Z 6)
 Estimated completion
09/2013
(continued on next page)
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are also drawbacks to using full antibody constructs
including long blood circulation time, slow clearance, and
high background signal. As key immunological effector
molecules themselves, these IgG tracers have inherent Fc
region-dependent interactions with FcɣR-expressing im-
mune cells within the TME.23,45,46 As an alternative,
engineered antibody fragments including single-chain
variable fragments (scFv; minibodies) or scFv dimers
(diabodies) and high-afﬁnity low-molecular weight pep-
tides have been evaluated as potential immuno-PET ra-
diotracers. The rapid clearance kinetics of noneIgG-based
agents enhance their capacity to integrate into clinical
workﬂow, can reduce the absorbed dose of ionizing radi-
ation, and may provide a means to serially monitor im-
mune targets of interest with greater frequency.
To that end, Chatterjee et al. have reported that 64Cu-
WL12, which is a high-speciﬁcity human PD-L1 binding
peptide, rapidly detects PD-L1-expressing cells within 60
minutes of administration with favorable intratumoral
accumulation and low background uptake.56 Similarly,
Mayer et al. introduced a small, engineered protein binder
that is derived from the ectodomain of PD-1 with high-
afﬁnity for human PD-L1.46 The small, engineered pro-
tein binder scaffold for PD-L1 immuno-PET exhibited
rapid clearance and high speciﬁc uptake.
Immuno-PET for cancer immunotherapy has not been
limited to the assessment of the PD-1/PD-L1 axis. The
concept of using reporter gene transduced or directly
labeled lymphocyte populations for in vivo imaging with
PET is several decades old.57e59 Preclinical immuno-PET
studies have largely focused on the detection and moni-
toring of speciﬁc T-cell subsets. This has been accom-
plished by the speciﬁc targeting of cell-surface CD
molecule expression (CD3, CD8), or the detection of
molecules that represent an effector/activated T-cell
phenotype (interleukin [IL] 2, granzyme B; see Table 2).
Preclinical models of 89Zr-DFO-anti-CD3 immuno-PET
have demonstrated the ability to visualize homeostatic
T-cell populations in healthy mice as well as TIL in tumor-
bearing counterparts.60 These investigations demonstrated
an 11.5-fold increase in tumor-to-blood signal relative to
control and no change in the absolute CD3þ count, which
allays concerns about potential lymphodepletion. Howev-
er, DFO-anti-CD3 did skew the T-cell population toward a
CD8þ T-cell central/effector memory phenotype with a
relative decrease in CD4þ T-cells. Although not overtly
deleterious to antitumor immunity, the impact of radio-
labeling/chelation on the peripheral immunome should be
further investigated. Molecular imaging that uses radio-
labeled targeting molecules is generally assumed to operate




Trial Patient population phase/design Enrollment status/
anticipated completion









 Inoperable stage I lung cancer (1-6cm)
 Phase 1 study to determine MTD of Ad5-yCD/
mutTKSR39rep-ADP adenovirus
 Intratumoral injection of virus. Prodrug and
SBRT (48Gy / 4Fx) 48hrs after virus
administration
 [18F]FHBG PET will be administered to
quantify HSV-1 TK gene expression at baseline
and postadministration













 Metastatic pancreatic cancer
 Phase 1 study to determine toxicity of
combining IL-12 gene therapy with
chemotherapy
 Single intratumoral injection of oncolytic Ad5-
yCD/ mutTKSR39rep-hIL12 adenovirus
followed by prodrug
 Optional [18F]FHBG PET imaging to quantify
intensity, persistence and biodistribution of
HSV-1 TK gene expression in the pancreas
 Recruiting (n Z 9)
 Estimated completion
06/2021
11C, Carbon-11; [18F]FDG-PET, 2-deoxy-2-[ﬂuoro-D-glucose [18F]; 89Zr, Zirconium-89; AMT, 1-methyl-D-tryptophan; CD, cluster of differentia-
tion; FLT, ﬂuorothymidine; IDO, indolamine 2,3-dioxygenase; IHC, immunohistochemistry; IL, interleukin; MRI, magnetic resonance imaging;
MTD, maximum-tolerated dose; NSCLC, non-small cell lung cancer; PET, positron emission tomography; PD-1, programmed cell death protein 1;
PD-L1, programmed death-ligand 1; SBRT, stereotactic body radiation therapy; SOC, standard of care; SUV, standardized uptake value; TNBC,
triple-negative breast cancer.
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in the microdosing regime, which is a term used to refer to
nonpharmacologic relevant mass doses of pharmaceuticals
afforded by the pM sensitivity of PET imaging. This work
demonstrates that, despite these assumptions, the careful
validation of a given tracer is required when dealing with
lymphocyte populations whose targeting may modulate
status or lead to depletion.
Larimer et al. demonstrated that increased 89Zr-DFO-
anti-CD3 uptake correlated with improved tumor control in
a CT26 colon model, which highlights a predictive role for
anti-CD3 immuno-PET with anti-CTLA-4 ICB.61 Tavaré
et al. have extensively studied immuno-PET of endoge-
nous CD8þ T-cells using a 64Cu-radiolabeled minibody62
as well as an 89Zr-radiolabeled anti-CD8 cys-diabody.63
Encouragingly, the monitoring of systemic and intra-
tumoral CD8þ T-cell responses with immuno-PET ap-
pears feasible across various therapeutic models, including
adoptive cellular therapy (ACT), T-cell agonistic anti-
bodies, and anti-PD-L1 ICB. Camelid derived single-
domain antibody fragments (so called nanobodies) are an
emerging targeting vector class with several advantageous
properties.64 An 89Zr-radiolabeled pegylated nanobody that
speciﬁcally targets CD8 has shown similar capacity to
detect the presence of CD8þ TIL. Interestingly, homoge-
neous intratumoral uptake, when compared with more
heterogeneous patterns, correlated with improved response
to anti-CTLA-4 therapy.65
Intratumoral Granzyme B expression indicates the
presence of cytotoxic T-cells (or natural killer cells)
within the TME and active tumoricidal effector function.
To interrogate the presence of granzyme B, Larimer et al.
hypothesized that a short-lived Gallium-68 (68Ga; t1/2 Z
68 min) radiolabeled peptide-based (GZP) imaging-agent
speciﬁc to this enzyme could function as a predictive
biomarker for ICB.66 A preclinical therapeutic model of
dual ICB demonstrated that 68Ga-NOTA-GZP immuno-
PET on day 14 was able to differentiate responders and
nonresponders based on Granzyme B expression patterns.
The authors proposed that early quantitative imaging data
may be used to guide treatment intensiﬁcation for poor
responders or discontinuation of ineffective therapy to
mitigate unnecessary toxicity. OX40 has drawn attention
as a potential biomarker for immunotherapy because
OX40 expression is restricted to antigen-speciﬁc activated
T-cells.67
Promising preclinical work from Alam et al. reported
that 64Cu-DOTA-AbOX40 immuno-PET can detect
complex spatiotemporal trafﬁcking patterns of activated
T-cells after in situ vaccination with CpG oligodeox-
ynucleotides. Early (48 hours) OX40 radiotracer uptake
was predominantly detected within the tumor and tumor-
associated draining lymph nodes; however, OX40
expression patterns shifted to the spleen with persistent
activity in the regional nodes at day 9.67
An understanding of the dynamics of T-cell activation
and migration in relation to different immuno-oncology
agents could help optimize combination approaches as
timing and sequencing can dramatically inﬂuence syn-
ergy.68,69 Nucleoside analogs, such as [18F]-AraG, have
also demonstrated speciﬁcity for activated T-cells in
preclinical models70,71 and is currently under clinical
investigation (NCT03007719) as a noninvasive imaging
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strategy to assay T-cell activation in patients undergoing
anti-PD-1/PD-L1 ICB.
PET has a long-established role in the clinical evalu-
ation of metabolism, most notably through the use of
[18F]FDG for glucose ﬁxation. Immunometabolism is
now increasingly appreciated as an important determinant
of response to immunotherapy. The 1-methyl-D-trypto-
phan (AMT) radiolabel with short lived Carbon-11 (11C;
t1/2 Z 20 min) for
11C-AMT PET is being explored as a
surrogate for indolamine 2,3-dioxygenase (IDO) pathway
activation (Table 1), which has been associated with
immunosuppression and a potential immune evasion
mechanism after radiation therapy.72
The unprecedented success of chimeric antigen re-
ceptor T-cells in several hematological malignancies has
revolutionized ACT and ignited interest in this approach
for solid tumors. Accordingly, there is an unmet need to
noninvasively monitor the trafﬁcking of tumor-speciﬁc
T-cells.73 An early proof-of-principle study demonstrated
the ability of immuno-PET to detect antigen-speciﬁc
antitumor T-cells after ACT.57,74 A series of adoptive
transfer experiments with either antigen-naïve or tumor-
antigen experienced T-cells engineered to express the
herpes simplex virus type 1 thymidine kinase (HSV1-
sr39TK) PET reporter gene demonstrated that only
antigen-experienced T-cells successfully localized intra-
tumorally. This was denoted by increased tumor uptake of
radiotracer [18F]-FHBG, which is a high-afﬁnity substrate
for HSV-sr39TK, and the PET ﬁndings were corroborated
by an increased CD3þ T-cell inﬁltrate observed by IHC.
Recently, this approach has been successfully trans-
lated for patients with recurrent glioma who undergo IL-
13-targeted ACT.75 In this study, CD8þ cytotoxic T-cells
were engineered to express both HSV1-TK and IL-13-
zetakine gene constructs to allow the IL-13-directed
cytotoxic T-cells to be monitored with [18F]-FHBG
PET/MRI. Other PET-based approaches to monitor
in vivo T-cell trafﬁcking for ACT include the ex-vivo
direct radiolabeling of antigen-speciﬁc T-cells before
infusion.76,77
Integrating molecular imaging into
radiation/immunotherapy combinations
An early indication of the promise of immuno-PET for
radiation oncology is supported by preclinical studies of
89Zr-radiolabeled anti-PD-L1 to evaluate radiation-
induced PD-L1 upregulation in syngeneic HPV þ
HNSCC (MEER) and melanoma (B16F10) models.78 In
these experiments, pre- and postradiation therapy
immuno-PET/CT demonstrated both a histology-
dependent and radiation dose-dependent upregulation of
PD-L1 expression after fractionated radiation therapy (2
Gy in 4 or 10 fractions). Multiparametric ﬂow cytometry
conﬁrmed enhanced PD-L1 expression in the irradiated
TME, which was mediated predominantly via inﬁltrating
PD-L1-expressing CD11bþ myeloid cells. These ﬁndings
suggest that this immune subset could be a target of in-
terest for future molecular imaging endeavors and thera-
peutic combination studies.
Using a similar 89Zr radiolabeled anti-CTLA-4 IgG2a
immuno-PET approach, our group demonstrated that
stereotactic radiation (12 Gy in 1 fraction) enhances the
intratumoral accumulation of immunosuppressive CTLA-
4-expressing regulatory T-cells (Tregs) and may be an
important therapeutic target for radiation/immunotherapy
combinations.79,80 A recent proof-of-principle study lends
further validation to immuno-PET for preclinical combi-
nation studies and has provided insight into mechanisms
of tumor localization of activated T-cells after local tumor
irradiation (14 Gy in 1 fraction).81
As T-cells express CD25 (IL-2Ra) upon activation,
Hartimath et al. developed an [18F]FB-IL-2 agent as a
means to noninvasively detect and monitor in vivo tumor-
inﬁltration of activated (CD25-expressing) T-cells. Mice
bearing HPV-related TC-1 tumors underwent local radi-
ation with or without subsequent vaccination with an E6/
E7-encoding virus (SFVeE6,7). Intratumoral [18F]FB-IL-
2 uptake was signiﬁcantly enhanced among irradiated
mice compared with sham-irradiated controls, and the
addition of immunization further increased radiotracer
uptake. Interestingly, irradiated mice that were treated
with a CXCR4 inhibitor had dramatically diminished
intratumoral [18F]FB-IL-2 activity, which suggests the
reduced inﬁltration of activated T-cells and was corrob-
orated by reduced CD8þ TIL on IHC.81
Ultimately, these preclinical immuno-PET studies
provide a platform to improve our understanding of
mechanisms of synergy between radiation therapy and
various immunotherapeutic-based approaches to specif-
ically evaluate dose-fractionation schedules, relative
timing or sequencing, and dynamic spatiotemporal uptake
patterns in response to combination therapy.
As evidence of the clinical beneﬁt of metastasis-
directed therapy in the oligometastatic state continues to
mount,82e85 the role and utilization of focal radiation
therapy applied in the metastatic setting will become
increasingly important. Consequently, there is a growing
need for companion imaging tools to help assess both
local and systemic responses to radiation therapy. This
has received increased attention, given the advent of
ICB and the potential for radiation therapy to potentiate
a systemic antitumor immune response in addition to a
local control beneﬁt when combined with
immunotherapy.86
A growing union of molecular imaging and radiation
oncology is exempliﬁed by the evolution of prostate-
speciﬁc membrane antigen (PSMA)-based PET imaging
in prostate cancer. Radiation target delineation that is
informed by PSMA-PET imaging can plausibly be a near-
term reality in the deﬁnitive, adjuvant/salvage, and
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oligometastatic settings.87e89 A similar molecularly ori-
ented immuno-PET approach could be envisioned to help
guide radiation target selection for radiation/immuno-
therapy combinations. Indeed, radiation therapy is
postulated to be one of several therapeutics to introduce
inﬂammation into the TME and theoretically convert an
immunologically cold (non-T-cell inﬁltrated) tumor into a
hot tumor that is characterized by a T-cell inﬂamed
phenotype with a type I IFN signature and concordant
chemokine expression.90 The ability to noninvasively
detect and target cold tumors with radiation therapy could
help enhance immune recognition and boost antitumor
immunity. Therefore, the development of noninvasive
imaging strategies that target radiation-driven immuno-
modulation and immune-related molecular processes
could offer substantial gains to our existing understanding
of radio-immuno-oncology and ultimately alter thera-
peutic management.
Similar to immunotherapy, radiologic changes associ-
ated with radiation treatment effect can be challenging to
interpret at times and pseudoprogression is a well-
documented phenomenon, particularly after ablative ra-
diation therapy regimens.91e94 Functional imaging with
[18F]FDG PET for radiation/immunotherapy combina-
tions has demonstrated some promise but remains
nonspeciﬁc.95
A phase 1 trial of stereotactic body radiation therapy
(SBRT; 16-20 Gy in 1-3 fractions) followed by high-dose
IL-2 in a cohort of patients with renal cell carcinoma and
melanoma demonstrated an impressive 66.6% response
rate per RECIST (8 of 12 patients with partial or complete
response; Fig 1).96 Among the 8 responders, 7 partial
responses were reported per the CT-based RECIST
evaluation. However, 6 of 7 patients with a CT-deﬁned
partial response were considered to have complete re-
sponses per the [18F]FDG PET evaluation. These ﬁndings
highlight potentially clinically relevant differences be-
tween anatomic and functional imaging in the determi-
nation of response.
A report of an abscopal response by Golden et al. in a
patient with metastatic non-small cell lung cancer who
was treated with hypofractionated radiation therapy (6 Gy
in 5 fractions) to a hepatic metastasis with concurrent or
sequential ipilimumab demonstrated an increased [18F]
FDG uptake in an isolated nonirradiated supraclavicular
node on a surveillance [18F]FDG scan.97 The residual
tumor was also noted in this subsequently excised hy-
permetabolic node, but a comparison of this specimen
with adjacent nodal tissue resected several years before
radio-immunotherapy demonstrated the development of a
robust lymphocytic inﬁltrate that was characterized by the
presence of cytotoxic CD8þ T-cells and FoxP3 þ Tregs
with an enhanced CD8þ/FoxP3þ ratio relative to the
pretreatment specimen. As such, there are caveats in the
interpretation of nonspeciﬁc functional imaging as
increased avidity could represent progressive or recurrent
tumor versus inﬂammation because of an evolving anti-
tumor immune response or immune-related adverse event
(Fig 1).
Signiﬁcant strides have been made in preclinical
models to decipher immunological mechanisms of syn-
ergy. The available prospective clinical data have pro-
vided some insight into potential immuno-PET molecular
imaging targets via interrogation of the peripheral
immunome and evaluation of activation markers on
circulating T-cells or serum chemokines/
cytokines.86,96,98e100 Ultimately, a better understanding
of the human immune TME in response to radiation
therapy in irradiated and nonirradiated lesions and in
comparison with pretreatment baseline will be essential to
elucidate immunologically relevant targets for immuno-
PET studies in the future. Recent work by Luke et al. in
a cohort of patients undergoing multisite SBRT and
sequential pembrolizumab included paired pre- and post-
SBRT biopsies, and the test results demonstrated an
upregulated IFN-ɣ-associated gene signature in a subset
of nonirradiated tumors after SBRT. These ﬁndings
represent a step forward for this ﬁeld and identify
candidate tissue-based biomarkers that could be devel-
oped for future noninvasive biomarker assessments.101
Conclusions
Immuno-PET holds outstanding potential to transform
the biomarker landscape for immunotherapy, and efforts
are underway to translate this molecular imaging tech-
nology into the clinical setting to noninvasively monitor
responses to various immuno-oncology agents. The
interdependence of oncologic imaging and radiation
oncology suggests that noninvasive molecular imaging
will play a key role in an effort to deliver individualized,
biology-driven, precision radiation therapy.102,103
Combining radiation therapy with immunotherapy is a
potential game changer in oncology, but this potential is
yet to be realized. Immuno-PET imaging may hold a
critical role in delivering the valuable insight needed to
help unravel this complex partnership.
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